Skip to main content
Top
Published in: BMC Public Health 1/2022

Open Access 01-12-2022 | SARS-CoV-2 | Research

Quantitative comparison of SARS-CoV-2 nucleic acid amplification test and antigen testing algorithms: a decision analysis simulation model

Authors: Phillip P. Salvatore, Melisa M. Shah, Laura Ford, Augustina Delaney, Christopher H. Hsu, Jacqueline E. Tate, Hannah L. Kirking

Published in: BMC Public Health | Issue 1/2022

Login to get access

Abstract

Background

Antigen tests for SARS-CoV-2 offer advantages over nucleic acid amplification tests (NAATs, such as RT-PCR), including lower cost and rapid return of results, but show reduced sensitivity. Public health organizations recommend different strategies for utilizing NAATs and antigen tests. We sought to create a framework for the quantitative comparison of these recommended strategies based on their expected performance.

Methods

We utilized a decision analysis approach to simulate the expected outcomes of six testing algorithms analogous to strategies recommended by public health organizations. Each algorithm was simulated 50,000 times in a population of 100,000 persons seeking testing. Primary outcomes were number of missed cases, number of false-positive diagnoses, and total test volumes. Outcome medians and 95% uncertainty ranges (URs) were reported.

Results

Algorithms that use NAATs to confirm all negative antigen results minimized missed cases but required high NAAT capacity: 92,200 (95% UR: 91,200-93,200) tests (in addition to 100,000 antigen tests) at 10% prevalence. Selective use of NAATs to confirm antigen results when discordant with symptom status (e.g., symptomatic persons with negative antigen results) resulted in the most efficient use of NAATs, with 25 NAATs (95% UR: 13-57) needed to detect one additional case compared to exclusive use of antigen tests.

Conclusions

No single SARS-CoV-2 testing algorithm is likely to be optimal across settings with different levels of prevalence and for all programmatic priorities. This analysis provides a framework for selecting setting-specific strategies to achieve acceptable balances and trade-offs between programmatic priorities and resource constraints.
Appendix
Available only for authorised users
Literature
7.
go back to reference World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. Interim guidance. 11 September 2020. Geneva, Switzerland. World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. Interim guidance. 11 September 2020. Geneva, Switzerland.
8.
go back to reference European Centre for Disease Prevention and Control. Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK. Technical report. 19 November 2020. Stockholm, Sweden. European Centre for Disease Prevention and Control. Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK. Technical report. 19 November 2020. Stockholm, Sweden.
12.
go back to reference Pray IW, Ford L, Cole D, et al. Performance of an antigen-based test for asymptomatic and symptomatic SARS-CoV-2 testing at two university campuses - Wisconsin, September-October 2020. MMWR Morb Mortal Wkly Rep. 2021;69:1642–7.CrossRef Pray IW, Ford L, Cole D, et al. Performance of an antigen-based test for asymptomatic and symptomatic SARS-CoV-2 testing at two university campuses - Wisconsin, September-October 2020. MMWR Morb Mortal Wkly Rep. 2021;69:1642–7.CrossRef
13.
go back to reference Shah MM, Salvatore PP, Ford L, et al. Performance of repeat BinaxNOW SARS-CoV-2 antigen testing in a community setting, Wisconsin, November-December 2020. Clin Infect Dis. 2021; ciab309. Shah MM, Salvatore PP, Ford L, et al. Performance of repeat BinaxNOW SARS-CoV-2 antigen testing in a community setting, Wisconsin, November-December 2020. Clin Infect Dis. 2021; ciab309.
14.
go back to reference Pilarowski G, Lebel P, Sunshine S, et al. Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San Francisco. J Infect Dis. 2021; jiaa802. Pilarowski G, Lebel P, Sunshine S, et al. Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San Francisco. J Infect Dis. 2021; jiaa802.
15.
go back to reference Prince-Guerra JL, et al. Evaluation of Abbott BinaxNOW rapid antigen test for SARS-CoV-2 infection at two community-based testing sites - Pima County, Arizona, November 3-17, 2020. MMWR Morb Mortal Wkly Rep. 2021;70:100–5.CrossRef Prince-Guerra JL, et al. Evaluation of Abbott BinaxNOW rapid antigen test for SARS-CoV-2 infection at two community-based testing sites - Pima County, Arizona, November 3-17, 2020. MMWR Morb Mortal Wkly Rep. 2021;70:100–5.CrossRef
16.
go back to reference Pollock NR, Jacobs JR, Tran K, et al. Performance and implementation evaluation of the Abbott BinaxNOW rapid antigen test in a high-throughput drive-through community testing site in Massachusetts. J Clin Microbiol. 2021;59:e00083-21.PubMedPubMedCentral Pollock NR, Jacobs JR, Tran K, et al. Performance and implementation evaluation of the Abbott BinaxNOW rapid antigen test in a high-throughput drive-through community testing site in Massachusetts. J Clin Microbiol. 2021;59:e00083-21.PubMedPubMedCentral
17.
go back to reference James AE, Gulley T, Kothari A, Holder K, Garner K, Patil N. Performance of the BinaxNOW COVID-19 Antigen Card test relative to the SARS-CoV-2 real-time reverse transcriptase polymerase chain reaction assay among symptomatic and asymptomatic healthcare employees. Infect Control Hosp Epidemiol. 2021; 1–3. doi: https://doi.org/10.1017/ice.2021.20. James AE, Gulley T, Kothari A, Holder K, Garner K, Patil N. Performance of the BinaxNOW COVID-19 Antigen Card test relative to the SARS-CoV-2 real-time reverse transcriptase polymerase chain reaction assay among symptomatic and asymptomatic healthcare employees. Infect Control Hosp Epidemiol. 2021; 1–3. doi: https://​doi.​org/​10.​1017/​ice.​2021.​20.
18.
go back to reference Okoye NC, Barker AP, Curtis K, et al. Performance characteristics of BinaxNOW COVID-19 antigen card for screening asymptomatic individuals in a university setting. J Clin Micro. 2021; JCM.03282-20. Okoye NC, Barker AP, Curtis K, et al. Performance characteristics of BinaxNOW COVID-19 antigen card for screening asymptomatic individuals in a university setting. J Clin Micro. 2021; JCM.03282-20.
22.
go back to reference Frediani JK, Levy JM, Rao A, et al. Multidisciplinary assessment of the Abbott BinaxNOW SARS-CoV-2 point-of-care antigen test in the context of emerging viral variants and self-administration. Sci Rep. 2021;11(1):14604.CrossRef Frediani JK, Levy JM, Rao A, et al. Multidisciplinary assessment of the Abbott BinaxNOW SARS-CoV-2 point-of-care antigen test in the context of emerging viral variants and self-administration. Sci Rep. 2021;11(1):14604.CrossRef
23.
go back to reference Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in false-negative rate of reverse polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020;173:262–7.CrossRef Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in false-negative rate of reverse polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020;173:262–7.CrossRef
24.
go back to reference Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill. 2020;25:2001483.CrossRef Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill. 2020;25:2001483.CrossRef
Metadata
Title
Quantitative comparison of SARS-CoV-2 nucleic acid amplification test and antigen testing algorithms: a decision analysis simulation model
Authors
Phillip P. Salvatore
Melisa M. Shah
Laura Ford
Augustina Delaney
Christopher H. Hsu
Jacqueline E. Tate
Hannah L. Kirking
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2022
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-021-12489-8

Other articles of this Issue 1/2022

BMC Public Health 1/2022 Go to the issue